Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Drug Discovery

Background:

• High-density lipoprotein (HDL) biogenesis is linked to reduced atherosclerosis.
• The cell-surface protein desmocollin 1 (DSC1) has been identified as a negative regulator of HDL biogenesis.
• DSC1's function suggests it is a druggable target for promoting HDL biogenesis.

Purpose of the Study:

• To explore the potential of targeting DSC1 for HDL biogenesis promotion.
• To investigate docetaxel as a DSC1 inhibitor for atherosclerosis treatment.
• To evaluate the hypothesis that HDL biogenesis reduces atherosclerosis.

Main Methods:

• Review of existing literature on DSC1, HDL biogenesis, and docetaxel.
• Analysis of DSC1's role in apolipoprotein A-I sequestration.
• Examination of docetaxel's effects on HDL biogenesis and vascular smooth muscle cell proliferation.

Main Results:

• Docetaxel, an FDA-approved chemotherapy drug, promotes HDL biogenesis at low-nanomolar concentrations.
• Docetaxel inhibits atherogenic proliferation of vascular smooth muscle cells.
• Animal studies demonstrate docetaxel reduces dyslipidemia-induced atherosclerosis.

Conclusions:

• DSC1 represents a novel therapeutic target for promoting HDL biogenesis.
• Docetaxel serves as a model compound to validate DSC1 as a target for atherosclerosis prevention and treatment.
• Further research is warranted to explore the clinical application of DSC1-targeting therapies.